The HPV vaccine, or cervical cancer vaccine, is available to women aged 32 for either the bivalent or quadrivalent human papillomavirus vaccine. Different ages are adapted for different vaccinations, and women at the age of 32 can receive either the bivalent HPV or quadrivalent HPV vaccine. Among them, the bivalent HPV vaccine is suitable for the prevention of a variety of diseases caused by high-risk human papillomavirus types 16 and 18, such as cervical cancer. Quadrivalent HPV vaccine, the main component of which is HPV6, 11, 16, 18L1 protein, is mainly suitable for the prevention of cervical cancer, grade 1 cervical intraepithelial neoplasia, as well as grade 2 and 3 cervical intraepithelial neoplasia and carcinoma in situ caused by high-risk HPV types 16 and 18. Both the bivalent HPV vaccine and the quadrivalent HPV vaccine require 3 doses to be completed within one year. The bivalent HPV vaccine is recommended for 1 dose during the months of 0, 1, and 6. The 2nd dose can be given within 1 to 2 months after the 1st dose, and the 3rd dose can be given within 5 to 8 months after the 1st dose. Quadrivalent HPV is recommended to be administered in one dose in 0, 2 and 6 months, with an interval of at least 1 month between the first dose and the second dose, and at least 3 months between the second and the third dose. Some women may experience adverse reactions such as headache, fever, diarrhea, fatigue, etc., as well as localized erythema and swelling when receiving HPV vaccination, which can usually be relieved on their own within a short period of time. For women who are menstruating, pregnant or preparing for pregnancy and breastfeeding. It should be noted that HPV vaccination cannot replace routine cervical cancer screening or other measures to prevent HPV infection and sexually transmitted diseases. Women who need cervical cancer vaccination are advised to consult their doctors in advance and learn about precautions, etc. from them.